The impact of PSA testing frequency on prostate cancer incidence and treatment in older men

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 4, 2011, Pages 332-339

  Shao, Y H ^a,b   Albertsen, P C ^c   Shih, W ^a,d   Roberts, C B ^e   Lu Yao, G L ^a,b,f  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f Dean and Betty Gallo Prostate Cancer Center   (United States)

Author keywords

medicare; PSA; SEER program; treatment

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; AGED; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

AGED; AGED, 80 AND OVER; HUMANS; INCIDENCE; MALE; MASS SCREENING; MEDICARE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES;

EID: 80955151467     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.29     Document Type: Article

References (31)

1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-916. (Pubitemid 17147932)
2. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002; 325: 740.
3. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-1984. (Pubitemid 40638368)
4. Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw 2010; 8: 240-262.
5. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 1708-1717.
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
7. Shao YH, Albertsen PC, Roberts CB, Lin Y, Mehta AR, Stein MN et al. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med 2010; 170: 1256-1261
8. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 185-191.
9. Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P et al. Prostate specific antigen testing among the elderly-when to stop? J Urol 2009; 181: 1606-1614; discussion 1613-1604.
10. Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA 2006; 296: 2336-2342. (Pubitemid 44749361)
11. Hudson SV, Ohman-Strickland P, Ferrante JM, Lu-Yao G, Orzano AJ, Crabtree BF. Prostate-specific antigen testing among the elderly in community-based family medicine practices. J Am Board Fam Med 2009; 22: 257-265.
12. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40 (8 Suppl): IV-3-18.
13. Freeman JL, Klabunde CN, Schussler N, Warren JL, Virnig BA, Cooper GS. Measuring breast, colorectal, and prostate cancer screening with medicare claims data. Med Care 2002; 40 (8 Suppl): IV-36-42.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383. (Pubitemid 17055592)
15. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258-1267. (Pubitemid 32007842)
16. American Joint Committee on Cancer. Manual for Staging of Cancer, 5th edn. JB Lippincott: Philadelphia, 1997.
17. Hamilton AS, Gloeckler Ries L. Cancer of Prostate. In: Ries L, Young J, Keel G, Eisner M, YD L, M-J H (eds). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub: Bethesda, MD, 2007.
18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
19. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 1984; 40: 819-825.
20. Advisory Committee on Cancer Prevention. Recommendations on cancer screening in the European Union. Eur J Cancer 2000; 36: 1473-1478.
21. van der Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF, van der Kwast TH, Kirkels WJ, Schroder FH. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology 2006; 68: 615-620. (Pubitemid 44436477)
22. Roobol MJ, Grenabo A, Schroder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2-and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst 2007; 99: 1296-1303. (Pubitemid 47398681)
23. Merenstein D. A piece of my mind. Winners and losers. JAMA 2004; 291: 15-16.
24. Linder SK, Hawley ST, Cooper CP, Scholl LE, Jibaja-Weiss M, Volk RJ. Primary care physicians' reported use of pre-screening discussions for prostate cancer screening: a cross-sectional survey. BMC Fam Pract 2009; 10: 19.
25. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 192-199.
26. Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010; 304: 2373-2380.
27. Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part I: Framing the debate. Urology 1995; 46: 2-13.
28. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008; 100: 630-641.
29. Miles A, Cockburn J, Smith RA, Wardle J. A perspective from countries using organized screening programs. Cancer 2004; 101: 1201-1213. (Pubitemid 39100414)
30. Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000; 284: 1399-1405.
31. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302: 1202-1209.